| Literature DB >> 26599766 |
Wolfgang Marx, Daniel McKavanagh, Alexandra L McCarthy, Robert Bird, Karin Ried, Alexandre Chan, Liz Isenring.
Abstract
[This corrects the article DOI: 10.1371/journal.pone.0141119.].Entities:
Year: 2015 PMID: 26599766 PMCID: PMC4657915 DOI: 10.1371/journal.pone.0143675
Source DB: PubMed Journal: PLoS One ISSN: 1932-6203 Impact factor: 3.240
Extraction table of reviewed clinical trials.
| Author/Date | Bordia et al. 1997 | Bordia et al. 1997 | Janssen et al. 1996 | Jiang et al. 2004 | Lumb. 1994 | Srivastava 1989 | Verma et al. 1993 | Young et al. 2006 |
| Study design | Placebo-controlled trial | Placebo-controlled trial | Randomised, placebo-controlled cross-over trial | Randomized, open label, three-way cross-over trial | Randomised, double-blinded placebo-controlled cross-over trial | Open-label single-arm trial | Randomised placebo-controlled trial | Cross-over trial |
| Sample Size | N = 60 | N = 20 | N = 18 | N = 12 | N = 8 | N = 7 | N = 20 | N = 10 for each group |
| Total study period: | 3 months. | One day | 6 weeks (3x2 weeks) | 3x13 days, 14 days washout period between each study period. | 2x1 day, at least 14 days washout period. | 7 days | 14 days, high-calorie diet for first 7 days, high-calorie diet and ginger/placebo consumed for next 7 days. | 72 days, 4x washout period of 7–10 days, 5x7 days intervention consumed |
| Population | Patients with confirmed myocardial infarction | Patients with confirmed myocardial infarction | Healthy volunteers | Healthy male volunteers | Healthy male volunteers | Health female volunteers | Health male volunteers | Healthy & Hypertensive volunteers |
| Outcomes measured at: | Baseline, 1.5 months and 3 months. | Outcomes measured at: baseline, 4 hours post-consumption | Outcomes measured at day 12 and 14 of each study period. | Outcomes measured at multiple time points, starting 2 days pre-warfarin consumption to 7 days post-consumption | Outcomes measured immediately before, 3h, and 24h post consumption of ginger | Outcomes measured at baseline and 7 days post-consumption | Outcomes measured at baseline, 7, and 14 days | Outcomes measured at baseline and 7 days post-consumption for each intervention |
| Intervention | Dose: 4g per day of unstandardized capsules | Dose: 10g single dose of unstandardized capsules | Dose: 15g raw & 40g cooked ginger placebo, once per day. Contained within 125g custard | Dose: 3.6g (3x0.4g, thrice per day) of unstandardized capsules. Consumed with 25 mg dose of rac-warfarin, consumed once per study period. | Dose: 2g (4x500mg) dried ginger per day of unstandardized capsules | Dose: 5g raw ginger per day | Dose: 5g (4x625mg, twice per day) dry ginger powder of Unstandardized capsules. Consumed with 100g (2x50g) butter, 2 cups of milk, 8 slices of bread. | Dose: 1g dried ginger per day, either alone or in combination with 10mg nifedipine |
| Outcome | Platelet aggregation | Platelet aggregation | Thromboxane B2 production (Payton Aggregation Module) | Platelet aggregation | Platelet aggregation | Platelet thromboxane B2 production | Platelet aggregation | Platelet aggregation |
| - Agonist(s): ADP and Epi | - Agonist(s): ADP and Epi | - Agonist(s): AA | - Agonist(s): AA, ADP, collagen, ristocetin | - Agonist(s): ADP and Epi | - Agonist(s): ADP, Epi, collagen | |||
| - Method (Device, if reported): Turbidimetric | - Method (Device, if reported): Turbidimetric | - Method (Device, if reported): Turbidimetric (Chrono-log) | - Method (Device, if reported): Electrical impedance (Chrono-log) | - Method (Device, if reported): turbidimetric (ELVI-840) | - Method (Device, if reported): Turbidimetric (Chronolog 560) | |||
| Fibrinogen | INR | Bleeding time | ||||||
| Fibrinolytic activity | Plasma warfarin enantiomer protein binding & warfarin enantiomer concentrations | Platelet count | ||||||
| Urinary S-7-hydroxywarfarin | Thromboelastography | |||||||
| Results | Ginger had no significant effect on both measures of aggregation | Reduction of both measures of platelet aggregation when compared to placebo (p<0.05). | Both types of ginger had no significant effect on maximum thromboxane B2 production (p = 0.616) | No significant changes in any outcome | No significant changes in any outcome at any time point. | Ginger consumption resulted in a 37% inhibition of thromboxane B2 production (p<0.01). | Ginger significantly reduced platelet aggregation using both agonists when compared to placebo group (p<0.001). | Ginger combined with nifedipine resulted in a significant decrease in platelet aggregation (p<0.001). Ginger alone had no significant effect. |
| Country | India | India | Netherlands | Australia | UK | Denmark | India | Taiwan |
| Level of evidence | III-1 | III-1 | II | III-1 | II | III-3 | II | III-2 |
| Comment | Ginger had no significant effect on blood lipids or blood sugar. Results relating to fenugreek excluded from table. No mention of randomisation. P value not reported. | This study was detailed in same manuscript as previous study. | No placebo group was included in study. Results relating to ginkgo group excluded from table. P value not reported. | Results relating to onion group excluded from table. | Platelet aggregation reduced close to baseline but did not decrease further. | No placebo group. Unclear if participants were blinded. |
Abbreviations: AA, arachidonic acid; ADP, Adenosine Diphosphate; Epi, epinephrine; INR, International Normalised Ratio; TxB2, Thromboxane B2;.
* Indicates some study details were missing and that scoring was based on details available.